Published in Hepatology on September 01, 2006
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology (2008) 1.45
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci U S A (2008) 1.24
Overlap syndromes among autoimmune liver diseases. World J Gastroenterol (2008) 1.21
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr (2008) 1.13
Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol (2010) 1.08
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech (2013) 1.01
Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol (2013) 0.98
Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol (2008) 0.94
The current diagnosis and treatment of benign biliary stricture. Surg Today (2012) 0.86
Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol (2009) 0.83
Is preoperative histological diagnosis necessary before referral to major surgery for cholangiocarcinoma? HPB (Oxford) (2008) 0.81
Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB (Oxford) (2011) 0.81
Cholangiocarcinoma Secondary to Primary Sclerosing Cholangitis in Explanted Livers: A Single-Center Study in the South of Iran. Hepat Mon (2015) 0.79
The medical management of primary sclerosing cholangitis. Medscape J Med (2008) 0.79
Usefulness of steroid administration for diagnosis of IgG4-related sclerosing cholangitis. Int Surg (2013) 0.78
Unusual binding of ursodeoxycholic acid to ileal bile acid binding protein: role in activation of FXRα. J Lipid Res (2012) 0.77
Endoscopic and surgical management of primary sclerosing cholangitis. Medscape J Med (2008) 0.77
Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl (2011) 0.77
Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol (2010) 0.76
Recurrence of autoimmune liver diseases after liver transplantation: clinical aspects. Auto Immun Highlights (2012) 0.75
Secondary Sclerosing Cholangitis and Hodgkin's Lymphoma. Clin Med Insights Case Rep (2015) 0.75
Rapid progression of primary sclerosing cholangitis complicated with ulcerative colitis. Case Rep Gastrointest Med (2015) 0.75
Primary sclerosing cholangitis as an intractable disease. Intractable Rare Dis Res (2012) 0.75
A woman with recent jaundice and pruritus. Hepat Mon (2010) 0.75
Recurrence of cholestatic liver disease after living donor liver transplantation. World J Gastroenterol (2008) 0.75
Is there any association between non-Hodgkin's lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome? Dig Dis Sci (2007) 0.75
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 4.56
Mechanisms of hepatotoxicity. Toxicol Sci (2002) 4.13
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology (2004) 3.61
Diagnosis and management of primary sclerosing cholangitis. Hepatology (2010) 3.60
Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem (2006) 3.57
Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology (2006) 3.52
Acute liver failure: Summary of a workshop. Hepatology (2008) 3.49
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr (2006) 3.32
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Cholangiocarcinoma. Gastroenterology (2005) 3.15
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr (2006) 3.03
Cellular and molecular mechanisms of liver injury. Gastroenterology (2008) 3.02
Lysosomes in cell death. Oncogene (2004) 3.00
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res (2012) 2.85
Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology (2002) 2.64
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl (2015) 2.63
EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc (2007) 2.61
Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest (2012) 2.56
Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 2.51
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology (2003) 2.45
Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2009) 2.41
Optimal therapy of hepatitis C. Hepatology (2002) 2.40
Life and death by death receptors. FASEB J (2009) 2.39
A survey of liver transplantation from living adult donors in the United States. N Engl J Med (2003) 2.37
Cholangiocarcinoma. Clin Liver Dis (2008) 2.33
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol (2003) 2.29
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Coordinate expression of regulatory genes differentiates embryonic and perinatal forms of biliary atresia. Hepatology (2004) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg (2005) 2.23
A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol (2004) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology (2002) 2.19
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
This month at the NIH: NIH roadmap: accelerating medical discovery to improve health. Gastroenterology (2003) 2.16
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem (2007) 2.01
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut (2007) 1.99
Baseline Analysis of a Young α-1-Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal Hypertension. J Pediatr Gastroenterol Nutr (2015) 1.98
Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology (2002) 1.98
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest (2003) 1.96
Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology (2008) 1.95
Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology (2006) 1.93
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res (2004) 1.91
The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology (2008) 1.90
The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology (2008) 1.88
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology (2003) 1.86
Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet (2003) 1.85
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem (2009) 1.82
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology (2007) 1.81
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol (2004) 1.80
Extrahepatic anomalies in infants with biliary atresia: results of a large prospective North American multicenter study. Hepatology (2013) 1.80
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology (2013) 1.78
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis (2003) 1.76
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest (2003) 1.73
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (2011) 1.70
Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology (2010) 1.70
Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68
Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium. Hepatology (2007) 1.68
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology (2010) 1.67